Chemistry:Aderbasib
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H28N4O5 |
| Molar mass | 416.478 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Aderbasib (codenamed INCB7839) is a sheddase inhibitor that may suppress tumor cell proliferation.[1] Acting on multiple receptor classes and subclasses, aderbasib is observed to regulate the tumor necrosis factor of cancer cells.[2] Aderbasib was being developed by Incyte as a potential adjunctive treatment for metastatic breast cancer. Development was halted in 2011 after positive findings from Phase II trials were contradicted by further research.[3][4]
References
- ↑ "STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL". Ama-assn.org. http://www.ama-assn.org/resources/doc/usan/aderbasib.pdf. Retrieved 2012-10-13.
- ↑ "Aderbasib | CAS#791828-58-5". MedKoo. http://www.medkoo.com/Anticancer-trials/Aderbasib.htm. Retrieved 2012-10-13.
- ↑ Incyte (2011-09-19). "UBS 2011 Global Life Sciences Conference". http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDQwNjgzfENoaWxkSUQ9NDYyNTAzfFR5cGU9MQ==&t=1. Retrieved 2013-02-13.
- ↑ "Incyte Reports Third Quarter 2011 Financial Results And Provides Update On Key Clinical Programs" (Press release). BusinessWire. 2011-10-27. Retrieved 2013-02-13.
External links
 |
